Introduction
Research progress and discovery of new treatments in the health field are providing a great increase in women and men's life expectancy, thus increasing the number of people aged over 65 years old, who often have changes from the senescence, such as osteoporosis 1 . This is one of the most common diseases of bone, especially in elderly women, due to estrogen deficiency during the climacteric (postmenopausal period). The disease is characterized by low bone mass and loss of the bone microarchitecture, increasing risk of fractures 1,2 .
Hormone replacement therapy has an established role in preventing postmenopausal osteoporosis and relieving climacteric symptoms. Tibolone was first produced by Organon (West Orange, NJ, USA) as synthetic steroid with estrogenic, androgenic, and progestagenic properties. It has been used primarily for the prevention of postmenopausal osteoporosis and treatment of climacteric symptoms 3, 4 . Studies using ovariectomized rat model have confirmed that tibolone has a direct estrogenic effect on bone, decreasing bone resorption and maintaining both cortical and trabecular bone quality 4, 5 . However, other studies have recommended that special care should be taken in cases of excessive use of this drug compromising the biomechanical competence of bone material 6 .
The incidence of osteoporosis has even increased in the last decades, because of a higher life expectance. As osteoporosis fractures cause significant morbidity, mortality and costs to the public health system, the early detection is very important for establishing effective therapeutic strategies to prevent bone fractures 4, 7 .
Radiographs are often the first diagnostic modality that raises suspicion of bone diseases, as osteopenia or even osteoporosis, this last only when bone loss exceeds 30% to 50% 8 . Many characteristic sings on radiograms are indicative of "bone loss". The cancellous bone becomes rarefied, resulting in spontaneous fractures 7, 9 . Over the last years, in many radiological departments, computed radiography has replaced conventional radiography. The advent of digital imaging in radiology combined with the burst in computer technology has dramatically improved imaging techniques 7, 9 . Computed radiography has facilitated operational conveniences, that raise the possibility of a quantitative assessment of bone density, optimizing the diagnostic related to bone loss 7, 10 .
Considering the increase in life expectancy of women, and the constant study of the pathophysiological mechanism of osteoporosis, plus possible therapeutic methods such as administration of tibolone, the development of research related to the issues in question are needed. All these factors attracted us to the interest in studying the use of tibolone inserted in the protocol proposed in this paper, analyzing if the effect of this drug on the bones even with prolonged use and high dosage, would still be beneficial. As reported before, osteoporotic fractures, mainly in climacteric woman, can cause morbidity and mortality. Thus, the early detection of bone loss is essential for the choice of an efficient therapeutic strategy preventing those dreaded fractures.
So, the utilization of reliable diagnostic methods for this disease is important due to the incapacities and risks implicated.
In this work, the computed radiography system (CRS) was the chosen method to evaluate the bone optical density in femurs and tibias of previously ovariectomized rats treated with tibolone for a period of five months.
Methods
The experiment was carried out on 20 mature Wistar rats, 
Computed radiography
Computed radiographies of the bones were obtained at the Nuclear Instrumentation Laboratory (UFRJ), using CR 50P
Portable Computed Radiography Scanner (GE system), imaging plate IPX and an X-Ray micro focus tube (Fein focus system).
Some experimental parameters were selected and standardized, operating with 40 kVp, 125 mA, source-detector distance of 1500 mm, source-object distance of 300 mm, exposure time of 600s and magnification factor 5; the pixel size of the image was 50mm.
Digital images were used to determine the bone optical density and the cortical thickness in the left femur and tibia in all groups. Regions of Interest (ROIs) -femoral neck, femoral and tibial diaphysis and distal tibia -were chosen to measure the cortical thickness. Measurements were performed using the Image J software (Figure 1 ). The same software was used to determine the bone optical density of four other ROIs -femoral head, femoral neck, femoral condyle, and proximal tibia ( Figure   2 ). The bone optical density is based on the gray values of the radiographic image, so higher gray values in the scale represent less bone density. To this last analysis, which was performed to quantify the gray scale, we standardized a square of fixed size
(598 x 614 pixels), which was positioned in the ROIs described above. Next, we used the tool Analyze -Plot profile of the Image J software, which provided a curve shape varied depending on the shades of gray belonging to the selected region. The values obtained were converted to a profile and the area under the curve was calculated being considered as the optical density of that region. This calculation was made using the software GraphPad PRISM 5 for Windows. The standardization of parameters is necessary to minimize the occurrence of variables that can affect the outcome of final radiographic image, considering that, the squares of fixed size as described above were positioned with the cursor, in the same positions for all analysis, always comprising only the trabecular area of the selected ROIs. 
Statistical analysis
Results were expressed as mean ± standard error (SEM). 
Results

Cortical bone thickness
Cortical bone thickness in the femoral neck and distal tibia showed no significant differences among groups ( Figures   3A and 3B ). Femoral and tibial diaphysis cortical thickness was greater in control group than in OVX+T group (P<0.05), but no significant difference was found between OVX+T and OVX group
( Figures 3C and 3D) . Most studies in humans use a dose of 2.5 mg [14] [15] [16] , which corresponds to 0.041 mg/kg in a 60 kg woman. Some studies even recommend that a lower dose of 1.25 mg of tibolone would have the same beneficial effects in bone 14, 17 or would be even better 18 . The dose of tibolone used in the current experiment was considered high compared to the commonly used in humans.
Through allometric calculation 19 , it was found that the dose used
Influence of estrogen deficiency and tibolone therapy on trabecular and cortical bone evaluated by computed radiography system in rats in this study, 1 mg/day per animal represent a dose 24 times higher than the usual in humans.
Elderly women are at higher risk for hip fracture because of additional and relatively rapid bone loss due to estrogen deficiency by loss of the ovarian function and a longer average life span than men 6, 20 . As in humans, ovarian hormone deficiency in rats also accelerates bone remodeling. Both (rats and humans) exhibit similar changes in bone mass and structure at numerous skeletal locations following loss of estrogen 2, 4, 20 . Estrogen deficiency in humans causes both trabecular bone loss and architectural deterioration, giving rise of an increased incidence of osteoporotic fracture 4, 20, 21 . Several studies have demonstrated that estrogen replacement therapy can effectively prevent trabecular as well as cortical bone loss by reducing bone resorption, showing to reduce the risk of skeletal fractures 4, 20, 22 . The present study confirms the estrogenic effect of tibolone at the femoral head reducing the bone resorption, since an increased bone density was found when compared to the OVX group. Tibolone preserves bone mass like estrogens through an inhibition of ovariectomy-increased bone resorption 7 .
Studies indicate that the effects of ovariectomy may happen in a month or even less with bone loss characteristics very similar to old rats 3 . In our results, the femoral head of the OVX group showed significantly lower bone density compared to C group, so a probable bone loss happened in those regions due to OVX. These data are in agreement with a previous research through dual-energy X-ray absorptiometry (DXA), which found a significantly lower bone mineral density (BMD) in the proximal and distal femur regions of the ovariectomized group 23 . Previous study found that ovariectomy caused a significant decrease -51%
-of trabecular BMD, in the distal femur of OVX rats, compared to the sham group 24 . In our study, contrasting to the above, the density of the distal femur (femoral condyle) was analyzed by the gray level on CRS and there was no statistical difference between the groups.
The distal and proximal femoral regions contain both cortical and trabecular bone, being exquisitely sensitive to estrogen deprivation and many studies have reported that ovariectomy results in a rapid and profound osteopenia in these locations.
Previous reports have described the need to study both cancellous and cortical bone loss for screening of therapeutic agents in osteoporosis 20 . This prompted us to choose the femoral and tibial proximal and distal regions as ROIs for studying the cortical and trabecular bone resorption using the CRS.
The purpose of this study was to quantify cortical and cancellous bone changes induced by tibolone in OVX rats using the CRS and compared these results with those obtained in OVX and non-ovariectomized rats. No significant effect was found at skeletal sites dominated by cortical bone, including femoral neck, distal tibia and the diaphysis of both bones, being in accordance with previous observations 21, 24 . Moreover, trabecular bone is much more responsive to hormonal as well as pharmacological intervention than cortical bone 22 . In our findings, only one ROIfemoral head in rats treated with tibolone -showed a significant increase in bone density, indicating less bone loss; no significant difference was found between the groups in the other locations analyzed.
CRS is generally the first choice of diagnostic method to study bone diseases, since it is simpler, less expensive, and easier to use 25 . Tibolone is effective showing beneficial estrogen action in tissues such as vagina, vascular system and even the bone 5, 17 .
However, in the latter tissue, the administration of this drug for a long time and in higher dose did not improve the quality of cortical and trabecular bone in the regions analyzed. It's important to emphasize that despite this, tibolone was not harmful to the bone mass, since compared with the OVX group, the OVX + T showed similar histomorphometric parameters analyzed.
Thus, with the information obtained, one can raise a scientific question about the biological behavior of models studying drug's effect. If the drug is administered in excessive dosage or time, could cause bone changes that are unfavorable to the primary goal of therapy. However, we must be cautious in extrapolating these results to humans, so more research is needed about the issue. The new approach in this protocol and our results warn that care must be taken with new protocols with hormone replacement, especially considering that currently, women end up spending longer time using hormones due to a more prolonged period of post-menopause, always bearing in mind better quality of life.
Conclusions
Ovariectomy caused bone loss in the analyzed regions and tibolone administered in high dose showed not to be fully beneficial, but preserved bone mass in the femoral head. Finally, computed radiography system is an efficient method to identify bone loss process, and to evaluate potential therapies, as tibolone administration.
